New malaria vaccine schedule trial aims to protect infants

NCT ID NCT06879327

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: PATH Source: ClinicalTrials.gov ↗

First seen May 20, 2026 · Last updated May 22, 2026 · Updated 2 times

Summary

This study tests the R21/Matrix-M malaria vaccine in about 964 African infants to find the best timing for shots. Researchers compare a standard schedule (6, 10, 14 weeks) with two relaxed schedules (2, 4, 6 months and 3, 6, 9 months). The goal is to see which schedule works best with other routine vaccines and provides strong protection against malaria.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA VACCINES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Groupe de Recherche Action en Santé (GRAS)
RECRUITING

Ouagadougou, Burkina Faso

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institut de Recherche en Sciences de la Santé (IRSS)
RECRUITING

Bobo-Dioulasso, Burkina Faso

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MALARIA VACCINES